# US 2003/0203031 A1 · Immune modulation with polystyrene sulfonate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203031 A1
- Document ID: US20030203031A1
- Status: Published application
- Kind: A1
- Application number: 10/431,199
- Filed: 2003-05-07
- Published: 2003-10-30
- Earliest claimed: 2000-03-06
- Inventors: Kumarpal A. Shah
- Web page: https://patentgrep.com/patent/US20030203031A1

## CPC

- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/795: Polymers containing sulfur
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 15/36: containing microorganisms
- A61L 15/425: {Porous materials, e.g. foams or sponges}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Polystyrene sulfonate (PSS) is a known immune-modulation drug for complement inhibition. Our due diligent review of this drug identifies it as a broad-spectrum immune modulation drug that therapeutically impacts innate and adaptive immune functions. The drug is first of a class of drug that modulates immune responses in accordance to recent advances of immunology. The therapeutic applications with relation to HIV are detailed. A compound for modulating an immune response in medical application in the form of a hydrogel including an ultrapurified polymer, a complement modulator and a gelling agent is also detailed. In a first embodiment the hydrogel has a pore size between 50 kDa and 100 kDa which generally functions as an immune response inhibitor. In a second embodiment, the hydrogel has a pore size greater than 200 kDa which generally functions as an immune response activator. The hydrogel may be applied directly, used to coat foreign materials, or used to encapsulate cellular or non-cellular material.

## Claims

### Claim 1

A method of clinically treating a disease in a host, wherein said disease causes modulation of at least one of Factor D, Factor H and CD 4 in the host immune system, the method comprising the steps of:
providing polystyrene sulfonate;
coating the polystyrene sulfonate with a hydrogel to form an encapsulated polystyrene sulfonate, wherein the hydrogel includes a gelling agent for providing immunoisolatory functions to enable selective targeting of different immune diseases by the encapsulated polystyrene sulfonate; and
administering to the host an effective dose of the encapsulated polystyrene sulfonate for therapeutically and selectively modulating at least one of the Factor D, Factor H and CD 4 in the host immune system.

### Claim 2 (depends on 1)

The method of claim 1, wherein the selective targeting comprises selective binding of the Factor D and selective exclusion of the Factor H by the encapsulated polystyrene sulfonate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administering step further comprises contacting the encapsulated polystyrene sulfonate with at least one of blood, body fluid and mucous membranes of the host.

### Claim 4 (depends on 3)

The method of claim 3, wherein the encapsulated polystyrene sulfonate comprises a formulation selected from the group consisting of powders, liquids, tablets, suppositories, injectable mediums, inhalation formulations, toothpastes, microcapsules and ex-vivo devices.

### Claim 5 (depends on 1)

The method of claim 1, wherein the encapsulated polystyrene sulfonate is administered in combination with an immune modulating drug.

### Claim 6 (depends on 1)

The method of claim 1, wherein the encapsulated polystyrene sulfonate is administered in combination with a chemotherapeutic agent.

### Claim 7 (depends on 1)

The method of claim 1, wherein the encapsulated polystyrene sulfonate is administered in combination with a cytotoxic agent.

### Claim 8 (depends on 1)

The method of claim 1, wherein the encapsulated polystyrene sulfonate is administered in combination with a vaccine.

### Claim 9 (depends on 1)

The method of claim 1, wherein selective targeting of different immune diseases is enabled by selective binding of the Factor D by the encapsulated polystyrene sulfonate for treatment of complement activated diseases.

### Claim 10 (depends on 1)

The method of claim 1, wherein selective targeting of different immune diseases is enabled by selective binding of the Factor H by the encapsulated polystyrene sulfonate for treatment of diseases that cause immune evasions of cytotoxic immune responses.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CD 4 is therapeutically modulated to inhibit maturation of dendritic cells for transplant tolerance.

### Claim 12 (depends on 9)

The method of claim 9, wherein the complement activated diseases are of acute origin.

### Claim 13 (depends on 12)

The method of claim 12, wherein the acute complement activated diseases comprise acute respiratory distress (ARDS), severe burns, multiple trauma, sepsis, acute stroke, coronary by-pass surgery, angioplasty, myocardial infarction, disseminated intravascular coagulopathy, inhalation anthrax, plague, tularemia induced sepsis due to bioterrorism, complications due to hemodialysis or cardiopulmonary bypass procedures in heart surgery, and transplantation rejection reactions due to xenotransplants, cell transplants and organ transplants.

### Claim 14 (depends on 10)

The method of claim 10, wherein the diseases that cause immune evasion of cytotoxic immune responses comprise at least one of bacterial diseases, viral diseases, parasitic diseases and cancers.

### Claim 15 (depends on 1)

The method of claim 1, wherein the Factor D, the Factor H and CD 4 are all therapeutically modulated for the therapy of drug-resistant bacterial infections, drug-resistant viral infections and drug-resistant cancer metastasis.

### Claim 16 (depends on 1)

The method of claim 1, wherein the hydrogel comprises an ultrapurified alginate having an endotoxin content less than 700 E.U./g.

### Claim 17 (depends on 1)

The method of claim 1, wherein the gelling agent provides immunoisolatory functions by enabling a pore size of the hydrogel to be adjusted.

### Claim 18 (depends on 1)

The method of claim 1, wherein the gelling agent comprises CaCl.

### Claim 19 (depends on 1)

The method of claim 1, wherein the Factor H has a molecular weight of 150 kD and the Factor D has a molecular weight of 25 kD.

### Claim 20 (depends on 17)

The method of claim 17, further comprising the step of adjusting the pore size of the hydrogel to have a nominal molecular weight cutoff between 50 kD and 100 kD.

### Claim 21 (depends on 17)

The method of claim 17, further comprising the step of adjusting the pore size of the hydrogel to have a nominal molecular weight cutoff of at least 200 kD.
